BASIC CHARACTERISTICS OF ZIRCONIUM PHOSPHATE NANOPARTICLES LOADED WITH RHENIUM(III) / CISPLATIN SYSTEM

The actual problem of creating a nanoscale delivery form of a combined system of rhenium(III) complex / cisplatin system with enhancing each other’s actions, which has pronounced antitumor properties and low toxicity, is revealed in the work. The need to create combination drugs for the treatment of cancer caused by the toxic effects of many substances that are already used in practice and are effective. As a result of this work, inorganic layered zirconium phosphate nanoparticles loaded with a combined system of rhenium(III) complex / cisplatin were obtained. The intercalation process was monitored by electron absorption spectroscopy. In addition to the interaction of the rhenium(III) compounds with the phosphate groups of the nanoparticles, the interaction with the cisplatin was also recorded. The X-ray powder diffraction method shows an increase in the interlayer space of zirconium phosphate after the reaction, which indicates the success of intercalation. The obtained diffraction peaks indicate the incorporation of rhenium(III) complexes, cisplatin and the interaction products of these compounds into the interlayer space of zirconium phosphate. It was also observed that the presence of cisplatin increases the interlayer space upon intercalation of the rhenium(III) compound. This peculiarity indicates that cisplatin serves as a preintercalator in the system under study. By quantitative analysis, the percentage of rhenium(III) in the nanoparticles obtained was determined on the Re-Re quadruple bond. The quantitative determination of the intercalated rhenium(III) compound is based on the reaction of the substitution of the carboxylate groups of the Re-Re cluster moiety with Cl- in concentrated hydrochloric acid. Depending on the structural type of compound used, the content of rhenium(III) in the nanoparticles was 40-42 %. As can be seen from previous studies, the incorporation of rhenium(III) in the obtained nanoparticles is higher than in the nanoparticles without cisplatin, which indicates a successful combination of rhenium(III) compounds with cisplatin. Obtained nanoparticles of combined action have prospects for use in medical practice for the treatment of tumor diseases.